At a compound annual growth rate of 12.10%, the size of the worldwide Lancets market is projected to reach USD 5,193.27 Million in 2030.
The global lancets market was valued at USD 849.7 million in 2018. Demand in the lancets market is led mainly by the increasing prevalence of diabetes and the rising prevalence of infectious diseases globally. Lancets are used for diabetes / glucose checks, pediatric health checks, heel-stick diagnostic assessments, as well as with those with scarred accidents or serious burns. The factors driving market growth include growing occurrence levels of infectious and non-contagious diseases, rising diabetes prevalence and growing propensity to home treatment and home diagnosis.
Improving regulations on medical devices are likely to encourage the development of the lancet market in coming years. Regulatory bodies in established as well as emerging countries are enforcing such laws for medical devices to ensure that medical devices of superior quality are produced and put on the market. Therefore, a favorable regulatory situation has a beneficial impact on the development of the lancet industry. Low information of lancets in emerging and underdeveloped countries; however, will also hinder the development of the industry.
Lancets Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2030||USD 5,193.27 Million|
|Growth Rate||CAGR of 12.10 % during 2022-2030|
|Segment Covered||By Type, By End-User, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and Africa|
|Key Players Profiled||F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Terumo Medical Corporation, Bayer AG, HTL-STREFA S.A., Sarstedt AG & Co., Improve Medical Technology Co. Ltd, others.|
Key Segment Of The Lancets Market
Type, 2022-2030 (USD Million)
• Safety Blood Lancets
• Vacuum Blood Lancets
By End-User, 2022-2030 (USD Million)
• Hospitals &Clinics
• Blood Banks
Regional Overview, 2022-2030 (USD Million)
• Rest of Europe
• Rest of Asia Pacific
• Rest of South America
Middle East and South Africa
Frequently Asked Questions (FAQ) :
On 26 August 2010, the FDA and the Centers for Disease Control and Prevention (CDC) published a notice that the usage of blood lancets to collect blood from more than one individual presents a danger of bloodborne pathogens spreading. The Centers for Medicare and Medicaid Programs (CMS) released a Point of Care and Infection Prevention Assessment and Evaluation Memorandum in nursing homes describing the usage of lancet tools for more than one individual as failure requirements for infection control.
Therefore, single-use lancets, which reduce the likelihood of spreading bloodborne pathogens arising from repeated usage by patients, will include language in the packaging that defines the system as "one use only" and instructs for proper disposal. Blood lancet systems intended for repeated usage will also have user-validated guidelines for the cleaning and disinfection of the reusable lancet product base after and patient uses it. Manufacturers of blood lancets with a reusable tool base and single-use lancet blades will have guidelines for the proper disposal of single-use lancet blades in the packaging, including directions for usage and published, illustrated and graphic content accompanying the blood lancet unit.
In 2018, push button safety lancet segment dominated in terms of revenues and is likely to maintain its dominance by the end of 2025. High acceptance rate of push buttons due to effective sample retraction with the press of a single button is likely to fuel their market. These are also quick, convenient, pain-free and allow for proper collection of blood samples. In addition, diabetic patients preferring these lancets, sue to ease of use is anticipated to drive the segment growth in coming years. Hence, a significant portion of diabetic population relies on protection lancet push-button tools for monitoring blood glucose, stimulating business development.
During the forecast period, the glucose test-monitoring segment will see lucrative development. Growing the incidence of diabetes worldwide and rising availability of painless, easy-to-handle, and reliable lancet tools for gathering blood samples would allow patients to assess changes in diabetes treatment, fueling segment development over the expected time span.
The lancets market in Europe is expected to see significant growth over the forecast years. The rising incidence of diabetes would drive the development of the lancet industry within the region in future. According to the WHO, in the European region about 60 million people suffer from diabetes. Furthermore, a favorable regulatory scenario and expanded usage of self-handling diabetes medical devices would fuel demand for lancet products, fueling development in the regional industry.
Nevertheless, Asia Pacific is projected to emerge with highest CAGR over the forecast period as lancets adoption rates in countries including China, Japan, and South Korea are rapidly rising. In fact, the regulatory framework for medical devices in these countries is relatively less strict, which has encouraged the quick entry of new drugs and medical equipment into this sector.